

Supplementary Digital Content 1, Statistical Data

Fig. 1. PD-L1 expression on neutrophils at different time points after

CLP surgery and in different locations at 24 h after surgery.

Different time points (A):

CLP vs. Sham for all time points, p < 0.001

CLP 12 h vs. CLP 18 h, p=0.02; CLP 12 h vs. 24 h, p < 0.001; CLP 18 h vs. CLP

24 h, *p* < 0.001.

Different location (B):

BM vs. Blood, BM vs. PC, Blood vs. PC, p < 0.001.

BM = bone marrow; CLP = cecal ligation puncture; PC = peritoneal cavity;

PD-L1 = programmed death receptor 1 ligand 1.




Fig. 2. Comparison of CD11a, CD11b, CD16, CD18, CD54, CD62L, CD64, and CCR2 between neutrophils from sham operated mice, PD-L1⁺ and PD-L1⁻ neutrophils from CLP mice.

Percentage:

CD11a (A): Sham vs. PD-L1⁻, p = 0.048; SHAM vs. PD-L1⁺, p < 0.001; PD-L1⁻

vs. PD-L1⁺, *p* < 0.001;

CD11b (B): Sham *vs.* PD-L1⁻, *p* = 0.413; SHAM *vs.* PD-L1⁺, *p* = 0.939; PD-L1⁻ *vs.* PD-L1⁺, *p* = 0.457;

CD16 (C): Sham vs. PD-L1⁻, p < 0.001; SHAM vs. PD-L1⁺, p < 0.001; PD-L1⁻ vs.

PD-L1⁺, *p* < 0.001;

CD18 (D): Sham vs. PD-L1⁻, p = 0.233; SHAM vs. PD-L1⁺, p = 0.725; PD-L1⁻ vs. PD-L1⁺, p = 0.130;

CD54 (E): Sham vs. PD-L1⁻, p = 1.000; SHAM vs. PD-L1⁺, p = 0.881; PD-L1⁻ vs.

 $PD-L1^+$, p = 0.881;

CD62L (F): Sham vs. PD-L1⁻, p = 0.006; SHAM vs. PD-L1⁺, p < 0.001; PD-L1⁻

vs. PD-L1⁺, *p* = 0.001;

CD64 (G): Sham vs. PD-L1⁻, p < 0.001; SHAM vs. PD-L1⁺, p < 0.001; PD-L1⁻ vs. PD-L1⁺, p < 0.001;

CCR2 (H): Sham vs. PD-L1⁻, p < 0.001; SHAM vs. PD-L1⁺, p < 0.001; PD-L1⁻ vs. PD-L1⁺, p = 0.020.

MFI:

CD11a (A): Sham vs. PD-L1⁻, p = 0.041; SHAM vs. PD-L1⁺, p < 0.001; PD-L1⁻

vs. PD-L1⁺, *p* = 0.044;

CD11b (B): Sham vs. PD-L1⁻, *p* = 0.874; SHAM vs. PD-L1⁺, *p* = 0.960; PD-L1⁻ vs. PD-L1⁺, *p* = 0.914;

CD16 (C): Sham vs. PD-L1⁻, p = 0.022; SHAM vs. PD-L1⁺, p < 0.001; PD-L1⁻ vs. PD-L1⁺, p < 0.001;

CD18 (D): Sham vs. PD-L1⁻, p < 0.001; SHAM vs. PD-L1⁺, p < 0.001; PD-L1⁻ vs. PD-L1⁺, p = 0.006;

CD54 (E): Sham vs. PD-L1⁻, p = 0.044; SHAM vs. PD-L1⁺, p < 0.001; PD-L1⁻ vs. PD-L1⁺, p < 0.001;

CD62L (F): Sham vs. PD-L1⁻, p = 0.480; SHAM vs. PD-L1⁺, p = 0.652; PD-L1⁻

vs. PD-L1⁺, *p* = 0.796;

CD64 (G): Sham vs. PD-L1⁻, p < 0.001; SHAM vs. PD-L1⁺, p < 0.001; PD-L1⁻ vs.

PD-L1⁺, p = 0.005;

CCR2 (H): Sham vs. PD-L1⁻, p = 0.002; SHAM vs. PD-L1⁺, p = 586; PD-L1⁻ vs.

 $PD-L1^+$, p = 0.005.

CCR2 = C-C chemokine receptor type 2; PD-L1 = programmed death receptor 1 ligand 1.




Fig. 3. Migratory ability of neutrophils isolated from sham operated

mice, PD-L1⁺ and PD-L1⁻ neutrophils from CLP mice.

CLP vs. Sham, p = 0.003 (A); PD-L1⁺ vs. PD-L1⁻, p = 0.013 (B).

CLP = cecal ligation puncture; PD-L1 = programmed death receptor 1 ligand 1.




Fig. 4. Expression of MHC class II molecule, CD40, CD80, and CD86 on neutrophils isolated from CLP mice.

MHC-II (A): 0 h vs. 12 h, p = 0.421; 0 h vs. 18 h, p = 0.111; 0 h vs. 24 h, p < 0.001; 12 h vs. 18 h, p = 0.022; 12 h vs. 24 h, p < 0.001; 18 h vs. 24 h, p < 0.001; CD40 (B): 0 h vs. 12 h, p = 0.907; 0 h vs. 18 h, p = 0.019; 0 h vs. 24 h, p < 0.001; 12 h vs. 18 h, p = 0.025; 12 h vs. 24 h, p < 0.001; 18 h vs. 24 h, p < 0.001; CD80 (C): 0 h vs. 12 h, p = 0.831; 0 h vs. 18 h, p = 0.018; 0 h vs. 24 h, p < 0.001; 12 h vs. 18 h, p = 0.029; 12 h vs. 24 h, p < 0.001; 18 h vs. 24 h, p < 0.001; CD80 (C): 0 h vs. 12 h, p = 0.831; 0 h vs. 18 h, p = 0.018; 0 h vs. 24 h, p < 0.001; 12 h vs. 18 h, p = 0.029; 12 h vs. 24 h, p < 0.001; 18 h vs. 24 h p = 0.018; CD86 (D): 0 h vs. 12 h, p = 0.807; 0 h vs. 18 h, p = 0.185; 0 h vs. 24 h, p < 0.001; 12 h vs. 18 h, p = 0.273; 12 h vs. 24 h, p < 0.001; 18 h vs. 24 h p < 0.001; CD86 (D): 0 h vs. 12 h, p = 0.807; 0 h vs. 18 h, p = 0.185; 0 h vs. 24 h, p < 0.001; 12 h vs. 18 h, p = 0.273; 12 h vs. 24 h, p < 0.001; 18 h vs. 24 h p < 0.001; 12 h vs. 18 h, p = 0.273; 12 h vs. 24 h, p < 0.001; 18 h vs. 24 h p < 0.001.




Fig. 5. Influence of PD-L1 on neutrophils from CLP mice on lymphocyte apoptosis.

A. Direct *vs.* Indirect, p < 0.001; Direct *vs.* Sham, p < 0.001; Indirect *vs.* Sham, p = 0.015;

B. Co-PD-L1 *vs.* Co-Isotype, *p* < 0.001; Co-PD-L1 *vs.* Sham, *p* = 0.530;

Co-PD-L1 vs. PD-L1, p = 0.117; Co-PD-L1 vs. Isotype, p = 0.633; Co-Isotype vs.

Sham, p < 0.001; Co-Isotype vs. PD-L1, p < 0.001; Co-Isotype vs. Isotype, p <

0.001; Sham vs. PD-L1, p = 0.033; Sham vs. Isotype, p = 0.273; PD-L1 vs.

Isotype, p = 0.264.

CLP = cecal ligation puncture; PD-L1 = programmed death receptor 1 ligand 1.




Fig. 6. PD-L1 expression on neutrophils from patients with severe sepsis, sepsis after PCNL for infectious kidney stone, tumor and healthy volunteers.

Severe sepsis *vs.* Kidney stone, p = 0.009; Severe sepsis *vs.* Tumor patients p < 0.001; Severe sepsis *vs.* Volunteers, p < 0.001; Kidney stone *vs.* Tumor patients p = 0.550; Kidney stome *vs.* Volunteers, p=0.314; Tumor patients *vs.* Volunteers, p = 0.980. PCNL = percutaneous nephrolithotomy; PD-L1 = programmed death receptor 1

ligand 1.




Fig. 7. The correlation of neutrophil PD-L1 with marker of

immunosuppression and disease severity by linear regression analysis. A. Neutrophil PD-L1 & Lymphocyte PD-1, p = 0.139; B. Neutrophil PD-L1 & Monocyte HLA-DR, p = 0.010; C. Lymphocyte PD-1 & Monocyte HLA-DR, p =0.255. D. Neutrophil PD-L1 & APACHE II score, p = 0.021; E. Neutrophil PD-L1 & SOFA score, p < 0.001; F. Neutrophil PD-L1 & MODS, score p < 0.001. APACHE = acute physiology and chronic health evaluation; HLA-DR = human leukocyte antigen DR; MODS = multiple organ dysfunction syndrome; PD-1 = programmed death receptor 1; PD-L1 = programmed death receptor 1 ligand 1; SOFA = sequential organ failure assessment.




Fig. 8. Disease severity, duration of mechanical and LOS in ICU in

patients with different PD-L1 level on neutrophils.

* p < 0.05 by Mann-Whitney U test.

A. APACHE II score, p = 0.002; B. SOFA score, p = 0.001; C. MODS score, p < 0.001

0.001; D. mechanical ventilation, p = 0.033; E. LOS, p = 0.060.

APACHE = acute physiology and chronic health evaluation; HLA-DR = human

leukocyte antigen DR; ICU = intensive care unit; LOS = length of stay; MODS =

multiple organ dysfunction syndrome; PD-L1 = programmed death receptor 1

ligand 1; SOFA = sequential organ failure assessment.